Treatment Patterns of Patients With Mitral Valve Disease and Critical Neo‐LVOT Obstruction
Patients with severe MV disease at high-risk for LVOTO (LVOT < 150 mm<sup>2</sup>) after TMVR were overwhelmingly female and were most frequently assigned to medical therapy. Patients with severe MAC had higher rates of death. Treatment allocation was not independently associated with mortality. Novel transcatheter therapies are needed to definitively treat this high-risk population.
Authors
- William W. O’Neill (ORCID: https://orcid.org/0000-0002-3062-213X)
- Georgi Fram (ORCID: https://orcid.org/0000-0002-9506-604X)
- Pedro Engel Gonzalez (ORCID: https://orcid.org/0000-0002-4675-8883)
- Adnan Halboni (ORCID: https://orcid.org/0000-0001-8449-4623)
- Pedro Villablanca (ORCID: https://orcid.org/0000-0002-3126-8638)
- Dee Dee Wang (ORCID: https://orcid.org/0000-0002-5784-9924)
- Brian O’Neill (ORCID: https://orcid.org/0000-0001-5206-1639)
- Gennaro Giustino (ORCID: https://orcid.org/0000-0002-5400-9516)
- Tiberio Frisoli (ORCID: https://orcid.org/0000-0002-5482-9290)
- Jonathan Fang (ORCID: https://orcid.org/0000-0001-5611-8313)
Institutions
- Henry Ford Health System (US)
- Morristown Medical Center (US)
- Naples Anesthesia & Physician Associates (US)
- National Heart Centre Singapore (SG)
- Atlantic Health System (US)
Publication Details
- Journal
- Catheterization and Cardiovascular Interventions
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1002/ccd.70091
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00